Skip to main content

Glenmark becomes the First Pharmaceutical Company to launch Teneligliptin + Pioglitazone Fixed-Dose Combination Drug forType 2Diabetes in India

 

-          The innovative Fixed-Dose Combination will help improving the glycemic control among adult patients with insulin resistance, those whose diabetesis uncontrolled by metformin; and also those who require addition of Teneliglitptin and Pioglitazone asseparate drugs.

-          Launched under the brand name ZitaPlusPio, thedrug will increase the accessibility of quality drugfor effective diabetes management.

-          ZitaPlusPio is the only available DPP4 andGlitazone combination brand in India.


Mumbai, April 25, 2022:Glenmark Pharmaceuticals Limited (Glenmark), aninnovation-driven global pharmaceutical company has launched a novelfixed-dose combination (FDC) of a widely used DPP4 inhibitor (Dipeptidyl Peptidase 4 inhibitor),Teneligliptin, with Pioglitazone. This is the only available DPP4 andGlitazone combination brand in India for adultswithuncontrolledType 2 diabetes. Glenmark has launched this FDC under the brand name ZitaPlusPio,which contains Teneligliptin (20 mg) + Pioglitazone (15 mg), to be taken once a day.

 


Commenting on the development, Alok Malik, Group Vice President & Head, India Formulations– Glenmark Pharmaceuticals, said, “Diabetes is a key area of focus for Glenmark; a pioneer in providing access to the latest treatment options to diabetic patients in India. We are delighted to introduce this novelZitaPlusPio, which is the first of its kind in India; offering a world-class and affordable treatment option to adult diabetic patients.”

 

Glenmark is the first company in India to market the innovative FDC of Teneligliptin+ Pioglitazone, which is approved by the DCGI (Drug Controller General of India). This fixed dose combination will be useful for patients who require treatment with Teneliglitptin and Pioglitazone (as separate drugs) to improve glycemic control reducing Insulin Resistance.

 

Type 2 diabetics typically face issues of β cell dysfunction and insulin resistance. Glenmark’s FDC of Teneligliptin +Pioglitazone has the efficacy to tackle thesetwo most importantpathophysiologieswhich makes the FDCmore effective in managing uncontrolled Type 2 diabetes. The combination of Teneligliptin+ Pioglitazone will provide a synergistic approach wherein Teneligliptin will optimally improve β cell sensitivity, and Pioglitazone will effectively reduce insulin resistance.

 

Glenmark’s contribution to diabetes treatment

In 2015, Glenmark revolutionized the diabetes market by launching its DPP4 inhibitor – Teneligliptin in India, followed by an FDC of Teneligliptin + Metformin. Glenmark has a strong legacy of more than four decades of progress and innovation. In continuation towards its first time in India legacy, it has launchedFDC of Teneligliptin + Remogliflozin in 2021.

 

 

India is known to be the diabetes capital of the world. According to the International Diabetes Federation (IDF), the prevalence of diabetes in India is around 74 million adults, which is expected to increase to 125 million (nearly 70% increase) by 2045[i]. Out of these, 77% of patients have uncontrolled diabetes[ii].

 

------End------

 

About Glenmark Pharmaceuticals Ltd.

Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is an innovation-driven global pharmaceutical company with a presence across Specialty, Generics and OTC businesses. It focuses on the key therapeutic areas of respiratory, dermatology and oncology. The company has 10 world-class manufacturing facilities spread across 4 continents and operations in over 80 countries. Glenmark is ranked among the world’s top 100 biopharmaceutical companies (Top 100 Companies Ranked by Pharmaceutical Sales, 2020, by In Vivo/Scrip 100) and among the world’s top 50 companies in the off-patent sector (Top 50 Generics and Biosimilars Companies ranked by Sales, 2020, by Generics Bulletin/In Vivo). The company was listed on the Dow Jones Sustainability Index (DJSI), one of the world’s most respected and widely accepted sustainability benchmarks, under the category of emerging markets (2021) for the fourth consecutive year in a row. For more information, visit www.glenmarkpharma.com

 



 

 

 

Popular posts from this blog

छतरपुर जिला चिकित्सालय को मिलेअत्याधुनिक जांच उपकरण एस्सेल माइनिंग द्वारा सी-आर्म, रक्त जांच एवं अन्य उपकरण दान

 छतरपुर की स्वास्थ्य अधोसंरचना को मजबूत बनाने के ध्येय को आगे बढ़ाते हुए एस्सेल माइनिंग द्वारा शुक्रवार को छतरपुर जिला चिकित्सालय में अत्याधुनिक सी-आर्म इमेजिंग डिवाइस, हाई फ़्लो नैज़ल कैनुला समेत त्वरित रक्त जांच उपकरण एवं मोरचुरी फ्रीजर भेंट किया गया।  जिला कलेक्टर श्री संदीप जी आर ने फीता काटकर नई सुविधाओं का शुभारंभ किया। इस अवसर पर मुख्य चिकित्सा एवं स्वास्थ्य अधिकारी डॉ विजय पथोरिया एवं अस्पताल के अन्य अधिकारी-कर्मचारी उपस्थित रहे। नए उपकरणों के साथ छतरपुर जिला चिकित्सालय के सुविधाओं में वृद्धि होने के साथ ही हजारों नागरिकों को नई जाँचों का लाभ मिल सकेगा और त्वरित जांच प्राप्त हो सकेगी।कलेक्टर श्री श्री संदीप जी आर द्वारा इस अवसर पर अस्पताल परिसर में पौधा रोपण भी किया गया।  एस्सेल माइनिंग द्वारा लगातार छतरपुर जिले की स्वास्थ्य सेवाओं को उन्नत बनाने में सतत योगदान दिया जा रहा है। पूर्व में गुरुवार को कंपनी द्वारा बक्सवाहा के सामुदायिक स्वास्थ्य केंद्र को बड़ा मलहरा विधायक श्री प्रद्युम्न सिंह लोधी की उपस्थिति में एडवांस्ड लाइफ सपोर्ट एम्बुलेंस भेंट की गई। वेंटीलेटर जैसी सुविधाओं के सा

*Reusable pads essential to make menstrual hygiene sustainable for all women and girls*

 If every woman and girl of menstruating age in India used disposable pads, 38,500,000,000 used pads would be discarded every month – an environmental disaster since each of these would take 500-800 years to degrade naturally XXX / May 26, 2021: Considering the immense non-biodegradable waste generated by disposable sanitary pads every month, sustainable menstrual hygiene in India can be achieved only with reusable pads made of organic material, said Anju Bist, Co-Director, Amrita SeRVe (Self Reliant Village) Program of Mata Amritanandamayi Math. Known as the “Pad Woman” of India for her zeal in promoting the use and reuse of sanitary pads made of cloth and banana fibre, she is the co-creator of Saukhyam Reusable Pads which have been awarded as the "Most Innovative Product" by the National Institute of Rural Development, Hyderabad. The pads were also lauded at the UN Climate Change Conference held in Poland in 2018. Said Anju Bist: “There are 355 million menstruating women an

*GLENEAGLES GLOBAL HEALTH CITY PERFORMS WORLD’S SECOND SUCCESSFUL PEDIATRIC COMBINED LIVING DONOR LIVER AND KIDNEY TRANSPLANT FOR A RARE GENETIC LIVER DISORDER*

 12-year-old boy with rare liver disease undergoes successful multi-organ transplant making him the 2nd case in the world and 1st in the country Chennai, 7th December, 2021: Gleneagles Global Health City (GGHC), a leading multi-organ transplant centre in Asia, successfully performed India’s first live donor liver and kidney transplant on a 12-year-old who was suffering from a rare genetic disorder – Primary Hyperoxaluria type 2. Master Anish*, a 12-year-old, was referred from Bangalore with renal failure and had been on dialysis three times a week. Doctors in Bangalore had diagnosed him with a rare genetic disorder called Primary Hyperoxaluria (PH) type- II, which is a liver condition that results in accumulation of oxalate in the kidneys, heart and bones and other organ systems of the body. As the disease is primarily based in the liver, these patients need combined liver and kidney transplantation for cure which is a major undertaking, especially in a child.  Across the world, there